Lipid-Based Gliclazide Nanoparticles for Treatment of Diabetes: Formulation, Pharmacokinetics, Pharmacodynamics and Subacute Toxicity Study

International Journal of Nanomedicine - New Zealand
doi 10.2147/ijn.s235290
Full Text
Abstract

Available in full text

Date
Authors
Publisher

Informa UK Limited

Related search

Influence of Efavirenz and Nevirapine on the Pharmacodynamics and Pharmacokinetics of Gliclazide in Rabbits

Journal of Endocrinology and Metabolism
EndocrinologyMetabolismDiabetes
2011English

Pharmacokinetics and Pharmacodynamics of an Orally Disintegrating Tablet Formulation of Dexlansoprazole

Therapeutic Advances in Gastroenterology
Gastroenterology
2016English

Gender-Based Effects on Methylprednisolone Pharmacokinetics and Pharmacodynamics

Clinical Pharmacology and Therapeutics
Pharmacology
1993English

Pharmacokinetics and Pharmacodynamics of Suxamethonium

Anaesthesia and Intensive Care
Critical CareAnesthesiologyPain MedicineIntensive Care Medicine
1997English

Pharmacokinetics and Pharmacodynamics of Insulin Glargine 300 U/mL in the Treatment of Diabetes and Their Clinical Relevance

Expert Opinion on Drug Metabolism and Toxicology
MedicineToxicologyPharmacology
2016English

Study of GABA in Healthy Volunteers: Pharmacokinetics and Pharmacodynamics

Frontiers in Pharmacology
Pharmacology
2015English

Journal of Pharmacokinetics and Pharmacodynamics

Journal of Pharmacokinetics and Pharmacodynamics
Pharmacology
English

Formulation and Evaluation of Solid Lipid Nanoparticles Containing Levosulpiride

The Open Nanomedicine Journal
2017English

Formulation and Evaluation of Chitosan Solid Lipid Nanoparticles of Carbamazepine

Lipids in Health and Disease
BiochemistryEndocrinologyClinical BiochemistryMetabolismDiabetes
2012English

Amanote Research

Note-taking for researchers

Follow Amanote

© 2024 Amaplex Software S.P.R.L. All rights reserved.

Privacy PolicyRefund Policy